SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Shopify, Inc. is a global commerce company that provides essential internet infrastructure for commerce, offering trusted tools to start, scale, market, and run a retail business of any size. The Company's software enables merchants to run their business across all of their sales channels, including web and mobile storefronts, physical retail locations, social media storefronts and marketplaces. The Shopify platform provides merchants with a single view of their business across all of their sales channels and enables them to manage products and inventory, process orders and payments, fulfill and ship orders, build customer relationships, source products, leverage analytics and reporting and access financing, all from one integrated back office. The company was founded on September 28, 2004 and is headquartered in Ottawa, Canada.

Shopify Inc - Ordinary Shares - Class A (Sub Voting)

Shopify Inc

Shopify is trending after beating Q4 revenue expectations, providing strong guidance, and announcing a $2 billion share buyback, yet experienced a massive, immediate sell-off post-open that baffled many. The community is divided, with some seeing market manipulation and a buying opportunity at deeply oversold prices, while others point to broader 'AI fears' and rate-sensitivity impacting tech valuations.

Uber Technologies, Inc. is a technology platform, which engages in the development and operation of technology applications, networks, and product to power movement from point A to point B. The firm offers ride services and merchants delivery service providers for meal preparation, grocery, and other delivery services. It operates through the following segments: Mobility, Delivery, and Freight. The Mobility segment refers to products that connect consumers with Mobility Drivers who provide rides in a variety of vehicles, such as cars, auto rickshaws, motorbikes, minibuses, or taxis. The Delivery segment offers consumers the chance to search for and discover local restaurants, order a meal, and either pick-up at the restaurant or have the meal delivered. The Freight segment focuses on connecting Carriers with Shippers on its platform, and gives Carriers upfront, transparent pricing, and the ability to book a shipment. The company was founded by Oscar Salazar Gaitan, Travis Kalanick, and Garrett Camp in 2009 and is headquartered in San Francisco, CA.

Uber Technologies Inc

Uber is actively discussed following its latest earnings report, where an EPS miss and cautious guidance sparked a sell-off, despite robust revenue growth and record users, fueling community debate over its undervaluation and the market's reaction to competition from Lyft and strategic autonomous vehicle expansions.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is trending significantly higher as its management clarified that HBM4 production and customer shipments are ramping ahead of schedule, assuaging recent market concerns. The community is actively discussing strong demand exceeding supply in the AI memory sector, fueling optimism and celebrating the debunking of bearish narratives.

Lyft, Inc. engages in the provision and management of an online social rideshare community platform. It offers access to a network of shared bikes and scooters for shorter rides and first mile and last-mile legs of multimodal trips, information about nearby public transit routes, and Lyft Rentals to offer riders a view of transportation options when planning any trip. The company was founded by Marcus Cohn, John Zimmer, Rajat Suri, Matt van Horn, and Logan Green in 2007 and is headquartered in San Francisco, CA.

Lyft Inc - Ordinary Shares Cls A

Lyft Inc

Lyft is trending due to a significant stock sell-off following its mixed quarterly results and cautious guidance, which many in the community view as an overreaction given the announced $1 billion share buyback. Investors are actively debating the company's growth trajectory and competitive standing against Uber, alongside the ongoing long-term discussion around autonomous vehicle disruption.

Astera Labs, Inc. is a global semiconductor company, which engages in the provision of hardware and software solutions for AI and cloud infrastructure applications to solve data, memory, and networking bottlenecks. It operates through the following geographical segments: Taiwan, China, United States, and Other. The company was founded by Jitendra Mohan, Casey Morrison, and Sanjay Gajendra in October 2017 and headquartered in San Jose, CA.

Astera Labs Inc.

Astera Labs Inc

Astera Labs (ALAB) is experiencing significant discussion following its robust earnings beat and a strategic warrant agreement with Amazon committing to billions in product purchases, though the stock saw notable volatility as the community debates its high valuation against accelerating AI infrastructure demand.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Reported snags and delays in Apple's anticipated AI-powered Siri features are driving conversation, with the community debating whether this setback impacts the company's long-term AI strategy and justifies its current valuation. Many investors are weighing concerns about the delayed rollout against Apple's strong ecosystem and market-propping role.

Unity Software, Inc. engages in the developing video gaming software. It also provides software solutions to create, run and monetize interactive, real-time two-dimensional and three-dimensional content for mobile phones, tablets, consoles, and augmented and virtual reality devices. Its platform is used by developers, artists, and designers to build content for gaming, film, retail, automotive, architecture, engineering, and construction industries. The company was founded by Joachim Ante and David Helgason in 2004 and is headquartered in San Francisco, CA.

Unity Software Inc

Unity Software is trending following a significant post-earnings sell-off driven by a conservative Q1 revenue outlook, despite beating Q4 expectations. The community is sharply divided, with many viewing the dramatic decline as an overreaction or institutional manipulation, while others remain cautious about the company's growth trajectory amid broader AI concerns.

HubSpot, Inc. engages in cloud-based customer relationship management. Its platform includes marketing, sales, service, operations and content management system, as well as other tools, integrations and native payment solutions. It operates through the following geographical segments: Americas, Europe and Asia Pacific. The company was founded by Brian Patrick Halligan and Dharmesh Shah on April 4, 2005, and is headquartered in Cambridge, MA.

HubSpot Inc

HubSpot is experiencing a notable price decline, with community discussion centered on its recent earnings report and intense debate over whether AI poses an existential threat to its SaaS model or if the stock is simply oversold with strong fundamentals for a significant rebound.

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull Corp ($BULL) is trending following its announcement of a new consolidated market data feed for overnight trading, amidst significant community frustration regarding its recent declines and perceived underperformance. Investors are actively discussing the stock's strong, often negative, correlation with Robinhood and Bitcoin, with some holding out for strong upcoming earnings and a potential short squeeze to reverse its trend.

International Business Machines Corp. is an information technology company, which engages in the provision of integrated solutions that leverage information technology and knowledge of business processes. It operates through the following segments: Software, Consulting, Infrastructure, Financing, and Other. The Software segment combines hybrid cloud platform and software solutions to help clients become more data-driven, and to automate, secure, and modernize their environments. The Consulting segment focuses on integrating skills on strategy, experience, technology and operations by domain and industry. The Infrastructure segment offers solutions for hybrid cloud and is the foundation of the hybrid cloud stack. Infrastructure is optimized for infusing AI into mission-critical transactions and tightly integrated with IBM Software including Red Hat for accelerated hybrid cloud benefits. The Financing segment refers to the client and commercial financing, facilitating IBM clients’ acquisition of IT systems, software, and services. The company was founded by Charles Ranlett Flint and Thomas J. Watson Sr. on June 16, 1911 and is headquartered in Armonk, NY.

International Business Machines Corp.

IBM is trending after strong Q4 earnings and positive 2026 guidance highlighted robust software and AI growth; however, a subsequent market pullback, amplified by broader software sector fears and an ex-dividend adjustment, has the community actively debating if it's an oversold buying opportunity for the hybrid cloud and quantum computing leader.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The strategic review could include partnerships, joint ventures, mergers, acquisitions, licensing deals, or other transactions, according to Quince Therapeutics.</li><li>On January 29, QNCX shares plunged 91.5% after the company said it would halt clinical development of its lead asset Edsp.</li><li>Lucid Capital double-downgraded Quince Therapeutics to ‘Sell’ from ‘Buy’ late last month.</li></ul>Shares of Quince Therapeutics, Inc. (QNCX) surged nearly 60% in pre-market trading on Tuesday after the company announced that it has appointed LifeSci Capital as its exclusive financial advisor to support a restructuring effort and review strategic alternatives.The strategic review could include partnerships, joint ventures, mergers, acquisitions, licensing deals, or other transactions, according to the company. In addition to assessing these opportunities, LifeSci Capital will advise Quince Therapeutics on any potential restructuring of its liabilities.Quince, a late-stage biotechnology firm focusing on rare disease treatments, added that it will not provide updates during the review and will disclose developments only if its board approves a specific action or deems further communication necessary.<h2 class="st-heading-2">96% Market Value Erased In Just Over A Week</h2>Quince Therapeutics’ stock has been under heavy selling pressure lately. On January 29, QNCX shares plunged 91.5% after the company <a href="https://stocktwits.com/news-articles/markets/equity/qncx-stock-plummets-over-90-percent/cmyipqPR410">said</a> it would halt clinical development of its lead asset, dexamethasone sodium phosphate encapsulated in autologous erythrocytes (eDSP).The late-stage trial in 105 patients with Ataxia-Telangiectasia, a rare and inherited neurodegenerative disorder, did not meet statistical significance for its primary endpoint. The study also missed its key secondary goal. The stock declined a further 37% in the following session.<a href="https://stocktwits.com/symbol/QNCX">QNCX shares</a> have declined nearly 96% from January 28 to Monday’s close.<h2 class="st-heading-2">Wall Street Turns Bearish</h2>The results prompted Lucid Capital to double downgrade Quince Therapeutics to ‘Sell’ from ‘Buy’ with a price target of $0, down from $8. The firm noted that the program, which is Quince’s asset, will be discontinued, and, given that the company’s estimated cash and long-term debt are nearly equal, it sees no value in the shares.The company has also faced mounting financial pressure. In the third quarter of fiscal 2025, Quince reported a net loss of $13.3 million, more than quadrupling the $3.2 million loss from a year earlier. Total operating expenses jumped 130% to $13.4 million.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits flipped to ‘extremely bullish’ from ‘bearish’ a day earlier, amid ‘extremely high’ message volumes.<figure class="image"><img src="https://news.stocktwits-cdn.com/QNCX_jpg_46df9654d8.webp" alt="QNCX.jpg" width="927" height="111"><figcaption>QNCX's Sentiment Meter and Message Volumes at Premarket on Feb. 10, 2026 | Source: Stocktwits</figcaption></figure>One bullish user noted the high volumes in after-market trading.<stembedurl>https://stocktwits.com/Risley/message/644527590</stembedurl>However, one bearish user highlighted the company’s shortcomings in the clinical trial.<stembedurl>https://stocktwits.com/Marceltrade/message/644532523</stembedurl>Over the past year, the stock has slumped 91%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/nasdaq-sp500-futures-subdued-tsla-rblx-tsm-hood-kd-stocks-to-watch/cZbUbhPR4Y9">Nasdaq, S&amp;P 500 Futures Subdued After Dow Closes Above 50,000: Why TSLA, RBLX, TSM, HOOD, KD Are On Traders' Radar Today</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

A candlestick chart can be seen in a trading platform on a smartphone. Top U.S. firms announced record buybacks this year. (Photo by Silas Stein/picture alliance via Getty Images)

Why Is QNCX Stock Up 60% Pre-Market After A Near-Total Wipeout?

The company announced that it has appointed LifeSci Capital as its exclusive financial advisor to support a restructuring effort and review strategic alternatives.

This Nano-Cap Biotech Stock Soars 60% Pre-Market Just Days After A Near-Total Wipeout – Here’s What’s Driving The Move

Equity

<ul class="summary-bullets"><li>The National Defense Authorization Act for fiscal 2026 calls on the DoD to integrate FDA-approved breakthrough vascular repair technologies to fix severe artery injuries in arms and legs.</li><li>This would provide an off-the-shelf biologically active vascular conduit when autologous vein harvesting is not feasible, the NDAA states.</li><li>Humacyte says Symvess has been used on the battlefield in Ukraine, with none of the sixteen recipients showing any adverse events such as amputations or infections so far.</li></ul>Humacyte Inc. (HUMA) on Monday announced that the recently adopted FY2026 U.S. Department of Defense (DOD) Appropriations Act includes funding for the procurement of bioengineered blood vessels.The company stated that the DOD funding is intended to support the evaluation and incorporation of biologic vascular repair technologies for warfighters with traumatic vascular injuries.Humacyte stated that its product, Symvess, is the only human-derived bioengineered blood vessel approved by the U.S. Food and Drug Administration (FDA).<a href="https://stocktwits.com/symbol/HUMA">Humacyte shares</a> were up more than 30% in Monday’s opening trade. Retail sentiment on Stocktwits around the company trended in the ‘bullish’ territory at the time of writing.<h2 class="st-heading-2">What Does The NDAA Say?</h2>The National Defense Authorization Act (NDAA) for fiscal 2026 calls on the DoD to integrate FDA-approved breakthrough vascular repair technologies&nbsp;to fix severe artery injuries in arms and legs.This would provide an off-the-shelf biologically active vascular conduit when autologous vein harvesting is not feasible, the NDAA states.Autologous vein harvesting refers to the surgical removal of the patient’s own healthy vein, which is usually the great saphenous vein (GSV) in the leg. This is used as a graft, typically in coronary artery bypass grafting (CABG) or peripheral vascular surgery.“This historic, first-of-its-kind federal investment will help ensure our soldiers continue to have access to cutting-edge treatments and state-of-the-art care whenever and wherever they need it,” said Humacyte founder and CEO, Laura Niklason.<h2 class="st-heading-2">What Is Humacyte’s Symvess?</h2>Symvess is a human-derived biologic vessel&nbsp;used when urgent revascularization is needed to avoid imminent limb loss and an autologous vein graft is not feasible.The company says Symvess is off-the-shelf and ready to use, with no immune response observed to date. It also states that Symvess has low susceptibility to infection.Humacyte says Symvess has been used on the battlefield in Ukraine, with none of the sixteen recipients showing any adverse events such as amputations or infections so far.<a href="https://stocktwits.com/symbol/HUMA">HUMA stock</a> is up 26% year-to-date, but down 71% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/momentus-nasa-partnership-space-operations-mnts-stock/cZbvGE4R4o3">Momentus Partners With NASA For In-Orbit Servicing, Space Operations — MNTS Stock Rises Pre-Market</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

HUMA Stock Is Soaring Today – Here’s Everything To Know About The DOD Funding Fueling The Surge

The company stated that its product, Symvess, is the only human-derived bioengineered blood vessel approved by the U.S. Food and Drug Administration.

<ul class="summary-bullets"><li>The agreement resolves ongoing legal issues between the companies.</li><li>Maxeon will terminate all pending and potential patent enforcement actions against Aiko.</li><li>Maxeon's infringement case against Aiko featured a patent covering proprietary and core solar cell designs for rear or back contact technologies.&nbsp;</li></ul>Shares of Maxeon Solar Technologies (MAXN) popped over 19% in pre-market trading on Friday after the company signed a patent licensing agreement with Shanghai Aiko Solar Energy for Maxeon’s Back Contact solar cell and module technology.Under the deal, Aiko will gain rights to use all of Maxeon’s Back Contact patents outside the United States, including existing intellectual property and any new patents added over the next five years.The agreement also resolves ongoing legal issues between the companies. Maxeon will terminate all pending and potential patent enforcement actions against Aiko, while Aiko will end its efforts to invalidate Maxeon’s patents.<h2 class="st-heading-2">Maxeon's Lawsuits Against Aiko</h2>Maxeon Solar had initially filed a lawsuit before the Mannheim Regional Court concerning infringement of its patent in 2023. The patent covered proprietary and core solar cell designs for rear or back contact technologies, commonly known as All-Back Contact (ABC) or Interdigitated Back Contact (IBC) solar cells.&nbsp;In June 2024, Maxeon opened a second lawsuit against Aiko and several of its partners before the Unified Patent Court Local Division in Düsseldorf, claiming infringement of its patent EP3065184.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits for <a href="https://stocktwits.com/symbol/MAXN">MAXN</a> turned 'extremely bullish' from 'bullish' a day earlier, amid 'extremely high' message volumes.One user highlighted patent and infringement details.<stembedurl>https://stocktwits.com/Figs999/message/644253077</stembedurl>Another user spoke about the company's operations in the U.S.<stembedurl>https://stocktwits.com/MMACRON/message/644262887</stembedurl>The stock has gained around 30% so far in 2026.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Why Did MAXN Stock Surge 19% In Pre-Market Today?

The company signed an agreement with Shanghai Aiko Solar Energy under which Aiko will gain rights to use all of its Back Contact patents outside the U.S., including existing intellectual property and any new patents added over the next five years.

<ul class="summary-bullets"><li>Palladyne expects to complete the deliverables by the third quarter of 2026.</li><li>The contract projected to generate nearly $1 million in revenue for fiscal 2026.</li><li>The win positions Palladyne for a bigger involvement in future long-duration missile programs, the company said.&nbsp;</li></ul>Shares of Palladyne AI Corp. (PDYN) jumped more than 10% in pre-market trading on Tuesday after the company signed an agreement with a major U.S. defense prime contractor to supply a mission-critical subsystem supporting missile propulsion for an existing U.S. missile program.<a href="https://stocktwits.com/symbol/PDYN">PDYN shares</a> jumped 17% after the opening bell.Palladyne expects to complete the deliverables by the third quarter of 2026, with the contract projected to generate nearly $1 million in revenue for the year. The win also positions Palladyne for a bigger involvement in future long-duration missile programs, the company said.“Beyond the initial contract, we believe we are well positioned for growing annual revenues from this program,” said Ben Wolff, CEO of Palladyne AI.<h2 class="st-heading-2">Palladyne’s Latest Contracts</h2>This comes on the back of two recent contracts. Last month, Palladyne AI was awarded a contract by the Air Force Research Laboratory (AFRL) for project HANGTIME to enable autonomous systems to operate as a coordinated unit. The project will use Palladyne’s SwarmOS to connect drones, ships, satellites, and ground systems, allowing them to share intelligence, adapt in real time, and execute synchronized missions across domains.In a separate development, Palladyne’s subsidiary GuideTech secured a contract with Portal Space Systems to support next-generation maneuverable spacecraft. GuideTech will provide navigation, guidance, spacecraft modeling, embedded software, and avionics expertise, expanding Palladyne’s footprint into the space sector.Palladyne also released its FY2026 forecast, expecting revenue between $24 million and $27 million, representing significant growth driven by new contracts, rising customer demand, and the integration of recently acquired businesses.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits remained in the ‘extremely bullish’ territory over the past 24 hours, accompanied by ‘extremely high’ message volumes.<img src="https://news.stocktwits-cdn.com/PDYN_jpg_f922841080.webp" alt="PDYN.jpg">One user expects the stock to climb to $10. It is currently at $7.91.<stembedurl>https://stocktwits.com/Lando4/message/643785073</stembedurl>The stock has seen heavy buying interest so far in 2026, surging 84%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Palladyne AI Corp. logo is seen displayed on a smartphone screen. 

Why Did PDYN Stock Pop Over 10% In Pre-Market Today?

The company signed an agreement with a major U.S. defense prime contractor to supply a subsystem that supports missile propulsion.

Palladyne AI Stock Is Surging After Landing A Pentagon-Linked Missile Contract 

<ul class="summary-bullets"><li>Massimo stated that it plans to integrate its manufacturing scale and brand awareness with FST’s full-stack AI capabilities, including intelligent control platforms, health-technology modules, and proprietary AI middleware.</li><li>Its purchase consideration for 100% of FST’s equity ranges between $27 million and $35 million.</li><li>In December, the company announced plans to introduce the Sentinel 1500, a utility terrain vehicle featuring a fully enclosed factory cab with integrated heating and air conditioning, in the first quarter of 2026.</li></ul>Massimo Group (MAMO) shares declined more than 64% in Tuesday’s pre-market session after the company announced that it has signed a Letter of Intent (LOI) to acquire FST Development.Massimo stated that, as per the non-binding LOI, it will acquire 100% of the equity interests of FST, a company that specializes in intelligent hardware and AI-driven system-level solutions.<h2 class="st-heading-2">Why Does Massimo Want To Acquire FST?</h2>Explaining the rationale behind its intent to acquire FST, Massimo stated that it plans to integrate its manufacturing scale and brand awareness with FST’s full-stack AI capabilities, including intelligent control platforms, health-technology modules, and proprietary AI middleware.“The proposed transaction represents a major strategic milestone for Massimo, positioning the Company at the convergence of two rapidly expanding global trends: AI-enabled outdoor mobility and next-generation digital health robotics,” Massimo stated in its announcement.Massimo stated that the pre-money equity valuation of FST is between $38 million and $50 million. However, its purchase consideration for 100% of FST’s equity ranges between $27 million and $35 million.The company added that it may satisfy the purchase consideration either by issuing its common stock, or through cash, or via a combination of both.<h2 class="st-heading-2">What Does Massimo Do?</h2>Massimo is a Garland, Texas-based company that manufactures and distributes powersports vehicles, utility terrain vehicles (UTVs), electric mobility solutions, and related accessories.In December, the company announced plans to introduce the Sentinel 1500, a UTV featuring a fully enclosed factory cab with integrated heating and air conditioning, in the first quarter of 2026.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/MAMO">Massimo</a> trended in the ‘extremely bullish’ territory while message volumes were at ‘high’ levels.One user stated that the company’s terms set out in the LOI are “manageable if an agreement is reached in March.”<stembedurl>https://stocktwits.com/Aburose/message/643771817</stembedurl><a href="https://stocktwits.com/symbol/MAMO">MAMO stock</a> is down 21% year-to-date, but up 3% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/pltr-stock-upgrade-after-blowout-q4-palantir-clearest-ai-winner/cZbiqZLR4lF">PLTR Stock Surges On An Upgrade Following Blowout Q4, Analyst Calls It 'One Of The Clearest AI Winners'</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Trading digital board showing the data on global stock market crash. | Image source: Getty Images

Why Is MAMO Stock Falling Pre-Market Today?

Massimo stated that, as per the non-binding LOI, it will acquire 100% of the equity interests of FST, a company that specializes in intelligent hardware and AI-driven system-level solutions.

<ul class="summary-bullets"><li>The FDA’s concerns were limited to packaging, labeling, and administration issues, the company said.</li><li>Aquestive has already modified the pouch design, updated instructions for use, and revised labelling.</li><li>The firm is also targeting global expansion plans for Anaphylm after initiating regulatory discussions in Canada, Europe, and the U.K last year.</li></ul>Shares of Aquestive Therapeutics (AQST) surged more than 35% on Monday morning, after receiving a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) seeking approval of Anaphylm, a sublingual film to treat severe Type I allergic reactions.A CRL indicates that while a drug has not been approved in its current form, it allows the sponsor to address the issues raised by the FDA and seek re-approval.<h2 class="st-heading-2">FDA’s Concerns</h2>The FDA’s concerns were limited to packaging, labeling, and administration issues identified in a human factors validation study. The FDA noted that some users had difficulty opening the pouch and correctly placing the film, which could pose safety risks during emergency situations. The agency did not raise questions about the drug’s comparability data or manufacturing processes, the company said.To address the feedback, Aquestive has modified the pouch design, updated instructions for use, and revised labeling. The company plans to conduct a new human factors study alongside a single pharmacokinetics (PK) study requested by the FDA. No additional trials are required.Based on the initial review, Aquestive expects to resubmit the application as early as the third quarter of 2026 and will seek a rapid review.<h2 class="st-heading-2">Europe Update</h2>Aquestive is also targeting global expansion plans for Anaphylm after initiating regulatory discussions in Canada, Europe, and the U.K. in 2025. The European Medicines Agency indicated that no additional clinical trials are required, with submissions in Europe and Canada expected in the second half of 2026. The company also anticipates feedback from the U.K.’s MHRA in the first quarter of 2026.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits turned ‘bullish’ from ‘neutral’ a session earlier, amid ‘high’ message volumes.&nbsp;<img src="https://news.stocktwits-cdn.com/AQST_jpg_c092cd62f6.webp" alt="AQST.jpg">One user brushed off concerns about the CRL, noting there were no key issues.<stembedurl>https://stocktwits.com/BigGainTom/message/643649716</stembedurl>While the stock has gained nearly 35% over the past year, its year-to-date losses are around 40%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/precious-metals-extend-historic-rout/cZbg8EJR4kf">Gold, Silver Continue To Decline – Analysts Warn Of Crowded Trades As Precious Metals Extend ‘Historic Rout’</a> For updates and corrections, email newsroom[at]stocktwits[dot]com.

Why Did AQST Stock Jump 35% Today?

The company received a Complete Response Letter from the U.S. Food and Drug Administration for its New Drug Application seeking approval of Anaphylm, a sublingual film to treat severe Type I allergic reactions.

<ul class="summary-bullets"><li>Quince on Thursday announced that the primary endpoint in the late-stage trial evaluating the asset in 105 patients with Ataxia-Telangiectasia did not reach statistical significance.</li><li>The study further did not meet its key secondary endpoint though the therapy was generally well tolerated with no clinically meaningful safety concerns, the company said. &nbsp;</li></ul> Shares of Quince Therapeutics, Inc. (QNCX) closed 92% lower on Thursday after the company said that it has decided to cease clinical development of its lead asset, dexamethasone sodium phosphate encapsulated in autologous erythrocytes (eDSP).Quince <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20260129349326/en/Quince-Therapeutics-Announces-Topline-Results-from-Pivotal-Phase-3-NEAT-Clinical-Trial-of-eDSP-in-Ataxia-Telangiectasia">announced</a> that the primary endpoint in the late-stage trial evaluating the asset in 105 patients with Ataxia-Telangiectasia did not reach statistical significance.Moreover, the study did not meet its key secondary endpoint though the therapy was generally well tolerated with no clinically meaningful safety concerns, the company said. &nbsp;<h2 class="st-heading-2">What Is Ataxia-Telangiectasia?</h2>Ataxia-Telangiectasia (A-T) is a rare, inherited neurodegenerative disorder caused by mutations in the ATM gene, leading to progressive loss of coordination, small, visible blood vessels in the eyes/skin, a weakened immune system, and a high risk of cancer, typically appearing in early childhood with unsteady walking and balance issues.Patients with the condition have a median lifespan of approximately 25 to 30 years. There are no approved therapies for the disorder in any global market, as per Quince, though there are about 4,600 diagnosed patients with A-T in the U.S.Shares of the company edged up 2% after hours at the time of writing.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around QNCX shares rose from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume remained at ‘high’ levels.A Stocktwits user said that they are adding more shares in the company for the “epic return to glory.”<stembedurl>https://www.stocktwits.com/McGinvests/message/643354295</stembedurl>Another user termed the selloff as “brutal” and hinted at a possible bankruptcy filing.<stembedurl>https://www.stocktwits.com/SierraIndiaDavid/message/643354859</stembedurl><a href="https://stocktwits.com/symbol/QNCX">QNCX stock</a> has lost 84% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/krro-shares-jump-on-analyst-upgrades/cmyimzWR41O">KRRO Shares Jump 13% On Analyst Upgrades — What’s Driving The Optimism?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Shares of InMode have fallen nearly 12% over the past 12 months. 

Why Did QNCX Stock Plummet Over 90% Today?

The company announced that it has decided to cease clinical development of its lead asset dexamethasone sodium phosphate encapsulated in autologous erythrocytes (eDSP). 

<ul class="summary-bullets"><li>The clearance allows the clinical-stage biotech firm to move ahead with preparations for a planned Phase 1b registrational study.</li><li>Serina&nbsp;had previously received written feedback from the agency supporting its proposed registrational trial design under an NDA pathway.</li><li>The latest update follows a setback in November 2025, when the FDA placed a clinical hold on the application to initiate clinical trials.</li></ul>Shares of Serina Therapeutics (SER) surged more than 70% in pre-market trading on Thursday after the company announced that the U.S. Food and Drug Administration (FDA) cleared its Investigational New Drug (IND) application for SER-252, a therapy to treat patients with Parkinson’s disease.SER-252 is an experimental apomorphine-based therapy to provide continuous dopaminergic stimulation, an approach shown to ease levodopa-related motor complications such as dyskinesia in people with Parkinson’s disease.<a href="https://stocktwits.com/symbol/SER">SER stock</a> had surged nearly 35% in after-hours trading on Wednesday.<h2 class="st-heading-2">SER-252: What Next?</h2>The clearance allows the clinical-stage biotech firm to move ahead with preparations for a planned Phase 1b registrational study in patients with advanced Parkinson’s disease. The IND clearance follows extensive regulatory engagement between Serina and the FDA.The company previously received written feedback from the agency supporting its proposed registrational trial design under an NDA pathway.“With FDA alignment on a registrational development strategy under a 505(b)(2) NDA pathway, we believe SER-252 has a clear and efficient path forward toward addressing a significant unmet medical need,” said Steve Ledger, Chief Executive Officer of Serina Therapeutics.The latest update follows a setback in November 2025, when the FDA placed a clinical hold on Serina’s application to initiate clinical trials. That hold was tied to a request for additional information related to an excipient in the drug’s formulation, a non-active substance included in a drug formulation alongside the active ingredient. Serina emphasized that the FDA’s concerns did not involve SER-252’s active drug substance or its proposed mechanism of action.<h2 class="st-heading-2">Retail Reaction</h2>Retail sentiment on Stocktwits turned ‘extremely bullish’ from ‘bearish’ a day earlier, accompanied by ‘extremely high’ message volumes.<figure class="image"><img src="https://news.stocktwits-cdn.com/SER_jpg_f485987591.webp" alt="SER.jpg" width="927" height="114"><figcaption>SER's Sentiment Meter and Message Volumes in Premarket on Jan. 29, 2026 | Source: Stocktwits</figcaption></figure>One bullish user said the stock price could double with good volumes.<stembedurl>https://stocktwits.com/Targeted_Trading/message/643250368</stembedurl>Another user simply said “massive news”, and the stock could climb to $8. It is currently around $4.<stembedurl>https://stocktwits.com/madape/message/643249925</stembedurl>SER shares have shed more than 40% in the past year, though its year-to-date gains are over 25%.Read also: <a href="http://stocktwits.com/news-articles/markets/equity/nasdaq-sp500-futures-higher-meta-tsla-ser-mp-crml-stocks-to-watch/cmyidGCR4KJ">Nasdaq, S&amp;P 500 Futures Climb Ahead Of Apple Earnings: Why META, TSLA, MP, CRML, SER Are On Traders' Radar Today</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Why Did SER Stock Surge Over 70% In Pre-Market Today?

The U.S. Food and Drug Administration cleared its Investigational New Drug application for SER-252, a therapy to treat patients with Parkinson’s disease.

SER Stock Surges Over 70% Pre-Market After FDA Clears Path For Parkinson’s Therapy

<ul class="summary-bullets"><li>The contract is issued under the VA Federal Supply Schedule and includes pre-negotiated pricing.</li><li>The agreement provides more than nine million enrolled veterans access to&nbsp;esophageal&nbsp;precancer testing.</li><li>Trading in PAVM shares was halted at 09:58 ET.</li></ul>Shares of PAVmed Inc. (PAVM) jumped more than 250% on Wednesday morning after its subsidiary, Lucid Diagnostics Inc. (LUCD), won a contract from the U.S. Department of Veterans Affairs (VA) to supply its EsoGuard Esophageal DNA Test for detecting esophageal precancer across the VA healthcare system.The agreement provides more than nine million enrolled veterans access to&nbsp;esophageal&nbsp;precancer testing.<a href="https://stocktwits.com/symbol/PAVM">PAVM</a> was among the top trending tickers on Stocktwits at the time of writing. <a href="https://stocktwits.com/symbol/LUCD">LUCD</a> shares jumped 23% to their highest levels since May 2025.<h2 class="st-heading-2">Contract Details</h2>The contract is issued under the VA Federal Supply Schedule and includes pre-negotiated pricing that aligns with the Medicare reimbursement rate set by the Centers for Medicare &amp; Medicaid Services. This structure allows VA hospitals and clinics nationwide to procure EsoGuard through a single, standardized framework.“The VA operates at significant clinical and operational scale, and selection by a healthcare system of this size reflects the strength of the clinical evidence supporting EsoGuard,” said Shaun O'Neil, President and Chief Operating Officer of Lucid Diagnostics.&nbsp;&nbsp;Lucid Diagnostics focuses on early cancer prevention diagnostics, particularly for patients with gastroesophageal reflux disease who face an elevated risk of developing esophageal precancer and cancer.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment for PAVM on Stocktwits flipped to ‘extremely bullish’ from ‘bearish’ a day earlier, accompanied by ‘extremely high’ message volumes.<figure class="image"><img src="https://news.stocktwits-cdn.com/PAVMED_jpg_a10dfa8673.webp" alt="PAVMED.jpg" width="925" height="96"><figcaption>PAVM's Sentiment Meter and Message Volumes at 10:20 a.m. ET on Jan. 21, 2026 | Source: Stocktwits</figcaption></figure>Sentiment for LUCD changed to ‘bullish’ from ‘neutral’ a day earlier, while message volumes were ‘extremely high’.One user believes the news has ‘real value’.<stembedurl>https://stocktwits.com/pow7904/message/642397455</stembedurl>PAVmed implemented a 1-for-30 reverse stock split on January 2.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/gold-rises-to-record-highs-as-investors-seek-out-safe-haven-assets/cmUDMEjR4fK">Gold Jumps To All-Time Highs – Veteran trader Peter Brandt Says $8,000 An Ounce Is On The Cards</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

PAVM Stock Shot Up Over 250% Today – What’s The Deal With The Department of Veterans Affairs?

PAVM Stock - The company’s subsidiary, Lucid Diagnostics, secured a contract from the U.S. Department of Veterans Affairs to provide its EsoGuard Esophageal DNA Test for the detection of esophageal precancer.

The company’s subsidiary, Lucid Diagnostics, secured a contract from the U.S. Department of Veterans Affairs to provide its EsoGuard Esophageal DNA Test for the detection of esophageal precancer.

<ul class="summary-bullets"><li>The company posted a net income available to common shareholders of $89.1 million, compared to a net loss of $286.4 million in the third quarter 2024.</li><li>Its revenue also jumped to $277.9 million, compared to $175.4 million in the third quarter 2024.</li><li>The company said strong financial performance in the third quarter was led by the Capital Markets segment.&nbsp;</li></ul>BRC Group Holdings, formerly known as B.Riley Financial, rallied in after-market hours on Wednesday after it announced its delayed quarterly results.&nbsp;The company filed financial reports for three quarters within 120 days, achieving NASDAQ compliance ahead of the deadline, it said in a regulatory filing.&nbsp;<h2 class="st-heading-2">Q3 Results</h2>The company posted a net income available to common shareholders of $89.1 million, compared to a net loss of $286.4 million in the third quarter 2024. The company said basic and diluted earnings per common share were $2.91 compared to a loss per share of $9.39 in the third quarter 2024.Its revenue also jumped to $277.9 million, compared to $175.4 million in the third quarter 2024. The company said strong financial performance in the third quarter was led by the Capital Markets segment with $65.4 million in services and fee revenues, the highest quarterly total since the fourth quarter of 2023.“We are pleased with the third quarter financial results. B. Riley Securities had a very strong quarter across investment banking, advisory, and research and trading with equity and debt capital raises totaling approximately $10.5 billion while delivering product innovation,” Bryant Riley, Chairman and Co-Chief Executive Officer of BRC, said.&nbsp;“Our Communications segment produced strong cash flow, consistent with previous quarters. B. Riley Wealth enhanced products and services for clients, while reducing costs and integrating its back office,” he added.&nbsp;<h2 class="st-heading-2">B.Riley Woes</h2>BRC’s struggles to file timely earnings reports started after a turbulent period in 2024 when it grappled with soured investments, flaws in financial reporting and a U.S. civil investigation.Franchise Group was a key investor of BRC and its bankruptcy in late 2024 left B. Riley burdened with write-offs of hundreds of millions of dollars and it was unable to file its annual and quarterly reports with US regulators on a timely basis. &nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment around RILY trended in ‘extremely bullish’ territory amid ‘high’ message volume.&nbsp;One user predicted the stock could hit $15 on Thursday.<a href="https://stocktwits.com/SelectiveTrader/message/641848445">https://stocktwits.com/SelectiveTrader/message/641848445</a>Shares of RILY have jumped 53% over the past year.&nbsp; &nbsp;

Chairman, B. Riley & Co. Bryant Riley (L) and CEO, B. Riley & Co. Tom Kelleher. (Photo by Matt Winkelmeyer/Getty Images)

B.Riley Stock Soars Nearly 40% - What’s Behind The Move?

Company said it has filed its delayed quarterly reports and achieved NASDAQ compliance ahead of the deadline. 

BlackRock Institutional Trust Company N.A. - iShares Micro-Cap ETF

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $APP earnings on Wednesday?

IWC
iShares Micro-Cap ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest IWC News

IWCiShares Micro-Cap ETF